NASDAQ:CNTB

Connect Biopharma Competitors

$16.22

-0.19 (-1.16 %)

(As of 05/18/2021 03:45 AM ET)

Add

Compare

Today's Range

$15.90

▼

$16.55

50-Day Range

$14.43

▼

$18.50

52-Week Range

$14.27

▼

$23.29

Volume548 shs

Average Volume143,122 shs

Market Capitalization$932.71 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Connect Biopharma (NASDAQ:CNTB) Vs. SANA, RXRX, NUVB, SEER, IBRX, and IMCR

Should you be buying CNTB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Connect Biopharma, including Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Nuvation Bio (NUVB), Seer (SEER), ImmunityBio (IBRX), and Immunocore (IMCR).

Connect Biopharma vs. Sana Biotechnology Stock

Sana Biotechnology (NASDAQ:SANA) and Connect Biopharma (NASDAQ:CNTB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Profitability

This table compares Sana Biotechnology and Connect Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	N/A	N/A
Connect Biopharma	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Sana Biotechnology and Connect Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0	2	2	0	2.50
Connect Biopharma	0	0	3	0	3.00

Sana Biotechnology currently has a consensus price target of $40.00, indicating a potential upside of 106.40%. Connect Biopharma has a consensus price target of $29.50, indicating a potential upside of 81.87%. Given Sana Biotechnology's higher possible upside, research analysts clearly believe Sana Biotechnology is more favorable than Connect Biopharma.

Earnings & Valuation

This table compares Sana Biotechnology and Connect Biopharma's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
Connect Biopharma	N/A	N/A	N/A	N/A	N/A

Summary

Connect Biopharma beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

Connect Biopharma vs. Recursion Pharmaceuticals Stock

Connect Biopharma (NASDAQ:CNTB) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Recursion Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
Recursion Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Recursion Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	0	0	3	0	3.00
Recursion Pharmaceuticals	0	2	3	0	2.60

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Recursion Pharmaceuticals has a consensus target price of $33.20, indicating a potential upside of 48.21%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Recursion Pharmaceuticals.

Valuation and Earnings

This table compares Connect Biopharma and Recursion Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	N/A	N/A	N/A	N/A	N/A
Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Summary

Connect Biopharma beats Recursion Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Connect Biopharma vs. Nuvation Bio Stock

Connect Biopharma (NASDAQ:CNTB) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Nuvation Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Nuvation Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	0	0	3	0	3.00
Nuvation Bio	0	0	6	0	3.00

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 52.90%. Given Connect Biopharma's higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Nuvation Bio.

Valuation and Earnings

This table compares Connect Biopharma and Nuvation Bio's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	N/A	N/A	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Connect Biopharma vs. Seer Stock

Connect Biopharma (NASDAQ:CNTB) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Seer's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
Seer	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Seer, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	0	0	3	0	3.00
Seer	0	2	2	0	2.50

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Seer has a consensus target price of $66.3333, indicating a potential upside of 112.47%. Given Seer's higher possible upside, analysts plainly believe Seer is more favorable than Connect Biopharma.

Valuation and Earnings

This table compares Connect Biopharma and Seer's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	N/A	N/A	N/A	N/A	N/A
Seer	N/A	N/A	N/A	N/A	N/A

Summary

Connect Biopharma beats Seer on 2 of the 3 factors compared between the two stocks.

Connect Biopharma vs. ImmunityBio Stock

Connect Biopharma (NASDAQ:CNTB) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and ImmunityBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	0	0	3	0	3.00
ImmunityBio	0	0	1	0	3.00

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 49.16%. Given Connect Biopharma's higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than ImmunityBio.

Valuation and Earnings

This table compares Connect Biopharma and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Summary

Connect Biopharma beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Connect Biopharma vs. Immunocore Stock

Connect Biopharma (NASDAQ:CNTB) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Immunocore's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
Immunocore	N/A	N/A	N/A

Valuation and Earnings

This table compares Connect Biopharma and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	N/A	N/A	N/A	N/A	N/A
Immunocore	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Immunocore, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	0	0	3	0	3.00
Immunocore	0	1	2	0	2.67

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 45.24%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Immunocore.

Summary

Connect Biopharma beats Immunocore on 3 of the 3 factors compared between the two stocks.